Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifampin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 2/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifampin SCHEMBL14029509 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL13230041 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14922822 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14252040 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14927261 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL66289 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL15472876 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL22517710 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL22432205 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL19457678 | 1.00 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113674801-A | Mycobacterium tuberculosis drug resistance detection and analysis system based on Nanopore sequencer and construction method thereof | 杭州圣庭医疗科技有限公司 | 2021-11-19 | — | — | CN | disclosed |
| US-11040037-B2 | Therapeutic agents and methods | POP TEST ONCOLOGY LLC | 2021-06-22 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-105693867-B | People sDR5-Fc recombination fusion protein and its new opplication | 深圳市中科艾深医药有限公司 | 2019-09-17 | — | — | CN | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-107827957-B | Anti- clinic multi-drug resistant bacteria small peptide | 吴国球 | 2019-02-26 | — | — | CN | disclosed |
| EP-3344325-A1 | LOCAL ADMINISTRATION OF DRUGS FOR THE TREATMENT OF ASTHMA | Mercator Medsystems, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| CN-107827957-A | Anti- clinical multi-drug resistant bacteria small peptide | 吴国球 | 2018-03-23 | — | — | CN | disclosed |
| WO-2017040605-A1 | LOCAL ADMINISTRATION OF DRUGS FOR THE TREATMENT OF ASTHMA | MERCATOR MEDSYSTEMS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-3086646-A2 | PLANTS CONTAINING BENEFICIAL ENDOPHYTES | Indigo AG, Inc. (US) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015100431-A2 | PLANTS CONTAINING BENEFICIAL ENDOPHYTES | SYMBIOTA, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| CN-101547905-B | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV | 2015-01-28 | — | — | CN | disclosed |
| CN-101547907-B | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV | 2013-01-02 | — | — | CN | disclosed |
| CN-101282981-B | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | TARGANTA THERAPEUTICS INC | 2012-09-26 | — | — | CN | disclosed |
| WO-2011151619-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE | SUMMIT CORPORATION PLC (GB) | 2011-12-08 | — | — | WO | disclosed |
| CN-101547907-A | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-30 | — | — | CN | disclosed |
| CN-101547905-A | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-30 | — | — | CN | disclosed |
| CN-101058826-A | Haemophilus drug sensitive batten and preparation method thereof | SHANGHAI FOSUN BIOLOG BIOTECHN (CN) | 2007-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040037-B2 | Therapeutic agents and methods | NR1H4, NR3C1, NR3C2 | MAPT 4807/4885NR1I2 125/4885ABCB11 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.